Taysha Gene Therapies (TSHA) announced progress across the TSHA-102 pivotal program, an intrathecally delivered AAV9 gene therapy with disease modifying potential, in clinical evaluation for the treatment of Rett syndrome. TSHA-102 Program Updates and Overview: Dosed First Patient in REVEAL Pivotal Trial in the Fourth Quarter of 2025; Reached Written FDA Alignment on ASPIRE Trial and Data for Inclusion in BLA Submission to Enable Broad Label Following Type D Meeting. Anticipated Milestones: Completion of dosing in the REVEAL pivotal trial is expected in the second quarter of 2026; Completion of dosing in the ASPIRE trial is expected in the second quarter of 2026; Update on longer-term safety and efficacy data from Part A of the REVEAL Phase 1/2 trials is expected in the first half of 2026
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Taysha Gene Therapies price target raised to $11 from $8 at Wells Fargo
- Taysha Gene Therapies rated Buy versus Early-Stage at Goldman Sachs
- Taysha price target raised to $19 from $13 at Cantor Fitzgerald
- Citizens JMP healthcare analysts hold an analyst/industry conference
- FDA appoints Richard Pazdur as Director of CDER